Mind Medicine in its US$175 million underwritten public offering and concurrent private placement

Osler represented Mind Medicine (MindMed) Inc. as Canadian counsel in connection with its US$175 million underwritten public offering and concurrent private placement. Leerink Partners and Cantor acted as joint bookrunning managers for the underwritten offering and placement agents for the private placement, and RBC Capital acted as lead manager for the underwritten offering and placement agent for the private placement.  

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The Company is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

Osler, Hoskin & Harcourt LLP advised MindMed with a team consisting of Trevor Scott, Minji Park, Peter Horemans (Corporate) and Kim Maguire (Tax).